Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02756962 · ClinicalTrials.gov registry record · Phase 2
Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance
A Phase 2 study of Acute Myeloid Leukemia, sponsored by Washington University School of Medicine.
- Active
- Registry status
- Phase 2
- Development phase
- 107
- Enrollment target
- 3
- Study locations
NCT02756962: Active Phase 2 study of Acute Myeloid Leukemia, sponsored by Washington University School of Medicine.
NCT02756962 is a Phase 2 study of Acute Myeloid Leukemia that is active but no longer recruiting, run by Washington University School of Medicine. The registered enrollment target is 107 participants, roughly in line with the 115-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target. The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02756962, a Phase 2 study of Acute Myeloid Leukemia, is active but no longer recruiting, sponsored by Washington University School of Medicine.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 107 participants
- Enrollment target
- 3
- Study locations
Study Summary
The investigators will prospectively determine whether the relapse-free and overall survival in patients who have cleared their leukemia-associated mutations treated with standard consolidation chemotherapy is superior to what is expected based on historical controls. The investigators will also prospectively determine the relapse-free and overall survival of patients who have not cleared their mutations. Because the relapse rate of patients with persistent mutations is expected to be high, treatment with either standard of care consolidation therapy alone or alloSCT will be permitted, at the discretion of the treating physician.
Primary Outcome
* Relapse-free survival is the time from study enrollment (morphologic complete remission (CR) or morphologic complete remission with incomplete blood count recovery (CRi) is required) until documented disease relapse, or death from any cause. * CR=Defined as morphologic leukemia-free state, defined as less than 5% blasts in aspirate with marrow spicules and a count of ≥200 nucleated cells and no blasts with Auer rods or any persistence of extramedullary disease. In addition, ANC \>1000/μl and p
Conditions Studied
Interventions
- DRUG Cytarabine
- PROCEDURE Bone marrow aspiration
- PROCEDURE Allogeneic stem cell transplant
- PROCEDURE Punch skin biopsy
- DEVICE ClinSeq
Study Locations (3)
Florida
- University of Florida - Gainesville
Missouri
- Washington University School of Medicine - St Louis
New York
- University of Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 107 participants |
| Start Date | 2016-07-06 |
| Est. Completion | 2029-07-31 |
| Phase | Phase 2 |
What the registry record for NCT02756962 still lists
NCT02756962 is an interventional study that assigns participants to a tested intervention. The registered 107 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 115-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target.
The record links to 1 condition, with Acute Myeloid Leukemia appearing as the primary indexed condition, and to 5 interventions - of which Cytarabine is the first listed.
NCT02756962 reports a single indexed study location in Florida, Missouri, New York.
Frequently Asked Questions
What is clinical trial NCT02756962 about?
NCT02756962 is a clinical study titled "Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance". The investigators will prospectively determine whether the relapse-free and overall survival in patients who have cleared their leukemia-associated mutations treated with standard consolidation chemotherapy is superior to what is expected based on historical controls. The investigators will also pro...
What is the current status of trial NCT02756962?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 107 participants. The study started on 2016-07-06. Estimated completion is 2029-07-31.
What conditions does trial NCT02756962 study?
This clinical trial studies the following conditions: Acute Myeloid Leukemia.
What interventions are being tested in trial NCT02756962?
The interventions under investigation include: Cytarabine (DRUG), Bone marrow aspiration (PROCEDURE), Allogeneic stem cell transplant (PROCEDURE), Punch skin biopsy (PROCEDURE), ClinSeq (DEVICE).
Who is sponsoring clinical trial NCT02756962?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02756962 being conducted?
This trial has 3 study locations across Florida, Missouri, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Myeloid Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02756962's enrollment target sits among peer trials
107 74th of 306 higher than 233 of 306 other Acute Myeloid Leukemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acute Myeloid Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure
RECRUITING · Phase 2
-
Venetoclax + Azacitidine vs. Induction Chemotherapy in AML
RECRUITING · Phase 2
-
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
RECRUITING · Phase 2
-
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
RECRUITING · Phase 2
-
A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy
RECRUITING · Phase 2
-
Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05491668 · 107 participants
Physiological Assessment of Severe Coronary Stenosis for Informing Planned PCI
- NCT06041594 · 107 participants · NA
Treating Pulmonary Embolism With Laguna Thrombectomy System (TRUST)
- NCT06081426 · 107 participants · NA
Examining Neurobiological Mechanisms Underlying the Therapeutic Effect of the Ketogenic Diet in Bipolar Disorder (BD)
- NCT06527599 · 107 participants · NA
Screening in Trauma for Opioid Misuse Prevention - an Adaptive Intervention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI